Connect with us

Heartland

Massachusetts Senate primary begs the question: Which candidate loves legalization least?

Two Democratic heavyweights slug it out in the Sept. 1 primary. Both say they’re progressive—but have opposed legalization for years.

The post Massachusetts Senate primary begs the question: Which candidate loves legalization least? appeared first on Leafly.

Republished by Plato

Published

on

Two Democrats who have been longtime opponents of cannabis legalization are vying for a US Senate seat in Massachusetts, a state where the plant has been recreationally legal since 2016.

Rep. Joseph Kennedy III seeks to unseat incumbent Sen. Ed Markey in the Sept. 1 Democratic primary. Neither candidate has been a legalization leader—just the opposite, in fact.

Both historically embraced prohibition and stood firmly on the conservative side of drug reform legislation. That’s left them trailing the state’s voters, who enthusiastically approved medical legalization in 2012 and adult-use legalization in 2016.

Two Massachusetts heavyweights square off

Markey, a longtime Boston politician, represented the city in Congress from 1976 until 2013, when he won a special election to fill the remainder of Sen. John Kerry’s term. Kerry had resigned to become Barack Obama’s secretary of state.

Ed Markey’s been Boston’s man in Congress since 1976. Joseph Kennedy’s family is synonymous with Massachusetts liberalism. Now the two are battling over Markey’s Senate seat.

Markey won his first full term in 2014, and he now faces a formidable primary challenge from Kennedy, whose family name is practically synonymous with Democratic politics in the state.

After earning a law degree and serving in the Peace Corps, Kennedy spent his late twenties as a local prosecutor in the Cape Cod region before successfully running for Congress in late 2012. He’s retained his seat representing Massachusetts’s 4th Congressional District ever since.

Neither liked legalization—until lately

The two Democrats’ lack of broad-reaching drug reform policies surfaced early in the campaign. During a June 8 debate, moderator and journalist Ted Nesi asked both about their silence on the flourishing in-state marijuana industry. 

“I have supported legalization since it passed in Massachusetts,” Markey answered. “I made it public after it passed, but it was something I came out publicly in favor of before Congressman Kennedy did.”

Markey and Kennedy both cited racial injustice in marijuana-related arrests. Kennedy defended his prior opposition to recreational and medical use. “I’ve been clear about that position,” Kennedy said, in response to Nesi probing into his voting record. “I came out for the legalization of marijuana over a year ago, long before Senator Markey signed onto those bills.”

Recent action supporting legalization

“Those bills” Kennedy referenced are three pieces of legislation that Markey recently cosigned. In January 2019, he voted in favor of the VA Medicinal Cannabis Research Act requiring the Department of Veteran Affairs to conduct research and clinical trials into the medical benefits of cannabis for veterans.

A month later, he cosigned the Marijuana Justice Act, which would remove marijuana from the Controlled Substances Act. The proposed Act would make the plant federally legal and automatically expunge the record of anyone incarcerated on use or possession charges. In addition, it would create a reinvestment fund to benefit communities most affected by prior criminal legislation.

Markey remained silent on the state’s 2016 legalization vote but he’s been far more active, earlier than Kennedy, on federal legalization measures.

In January 2020, Markey cosigned the Marijuana Opportunity Reinvestment and Expungement Act, or MORE Act. This Act, widely seen as the most progressive federal legalization measure, also seeks to remove the substance from the CSA, allowing states to set their own legislation.

Markey refused to openly support cannabis reform prior to 2019, but he did vote in favor of measures to protect the legal marijuana industry’s access to banking services. In May 2017, he voted for the Secure and Fair Enforcement Banking Act, or SAFE Banking Act, which would prohibit federal regulators from penalizing or interfering with banks that serve state-legal cannabis companies. In September of the same year, he supported the Carers Act to remove CBD from the legal definition of marijuana and protect anyone legally possessing and using the plant medicinally.

In 2016, Markey stayed silent on legalization

In 2016, Massachusetts added recreational legalization to the general election ballot as a referendum question. Markey never spoke out in favor or opposition of Question 4, but recently stated in the second primary debate that he voted in favor of the referendum. Since it passed, Markey has claimed to have been a vocal proponent of drug policy reform. Many legalization leaders have chastised Markey for supposedly favoring Question 4 personally, but remaining silent when it mattered.

Prior to his assumption of the Senate seat, Markey served as a representative for Massachusetts’s 7th Congressional District from 1976 to 2013. In 2005, Markey voted for the Medical Marijuana Use Amendment that protects medical marijuana users from prosecution and arrest by the Department of Justice in states where the plant is legal. Two years later, he voted in favor of a similar amendment to the Commerce, Justice, Science and Related Agencies Appropriations Act that would prohibit the Department of Justice from using funds from that act to interfere with state legislation regarding medicinal marijuana use. 

Kennedy wasn’t any better

Though a newer face in the congressional circuit, Kennedy has had his fair share of both opposition to and support of marijuana legislation. Kennedy signed onto the MORE Act earlier this year. In June 2019, he voted in favor of an amendment that would prohibit the Department of Justice from overstepping state recreational and medical cannabis laws.

In early 2018, Kennedy opposed legalization because it helped cops bust people. But by the end of that year he was penning op-eds embracing legalization.

In Nov. 2018, Kennedy penned an op-ed article for Stat News titled “It’s time to legalize marijuana at the federal level.” In the piece, he called for cannabis to be removed from the Controlled Substances Act, and cited the grievous harm that racial disparities in marijuana arrests does to communities of color. In the same article, Kennedy acknowledged his prior support of marijuana prohibition: “My reluctance to embrace legalization stems primarily from one place: my ongoing work with the mental health and addiction communities.”

Kennedy made his pre-op-ed reluctance clear. In March 2018, he was quoted in a Vox podcast opposing decriminalization because the odor of marijuana gave police probable cause to search vehicles, leading to more arrests. In January of that year, then-attorney general Jeff Sessions rescinded a memo allowing states to regulate their own marijuana laws without federal interference. Though he is a lawmaker in a recreationally and medically legal state, Kennedy remained silent on the action taken by Sessions.

Kennedy raised money to stop legalization

In regard to 2016’s ballot Question 4, Kennedy sponsored a bipartisan fundraiser to block the referendum from taking effect. He raised money for Safe and Healthy Massachusetts, the state’s major anti-marijuana campaign organization. Patrick Kennedy, the former congressman and Kennedy’s first cousin once removed, co-founded and continues to lead—with Kevin Sabet—Smart Approaches to Marijuana (SAM), the nation’s most vocal anti-legalization advocacy group.

Kennedy has long been an opponent of medical cannabis use as well. In 2017, he voted against an amendment introduced by Republican Congressman Scott Perry to allow children with epilepsy access to CBD oil and therapeutic hemp.

Hard core: Voting against veterans access to MMJ

While Markey voted for a pro-legalization amendment to the Commerce, Justice, Science, and Related Agencies Act in 2007, Kennedy opposed a similar amendment designed to protect state laws from federal supersession in 2015.

For three years running, Kennedy voted against allowing military veterans access to medical marijuana trials.

In the same year, Kennedy voted against an amendment proposed by Rep. Tom McClintock to protect state legislature over marijuana in areas within each respective state’s jurisdiction.

Three years in a row, Kennedy opposed measures that would have allowed military veterans greater access to medical marijuana. In 2014, Kennedy voted against an amendment that would allow veterans to participate in state-approved medical marijuana trials. He voted against two similar amendments in the following years, once in 2015 and again in 2016.

But Kennedy’s suddenly for psilocybin?

As the race has heated up this summer, Kennedy has scrambled to position himself as the more progressive candidate. That pivot has included a surprising new openness to drug reform policies. During a town hall event in early August, Kennedy said he’s been “diving into some of the issues around the medicinal use of certain psychedelics that, at least at this point, show some promise with regards to addressing issues in depression and particularly PTSD.”

Kennedy added a call for “more study” of medically supervised psychedelic use, but last year he voted against an amendment in Congress introduced by Rep. Alexandria Ocasio-Cortez that would have expanded research into psychedelics like psilocybin and MDMA.

A race to claim the ‘most progressive’ crown

Markey has responded by touting his progressive congressional record through viral campaign videos, one of which dubbed him the “GreenNewDealmaker.” On Twitter in particular, he detailed his history supporting Medicare for All since its introduction in 2017 and called for more action from the federal government related to COVID-19 relief.

Unlike Kennedy, Markey has not publicly taken a stance on the study or use of psychedelics in the state. This month, his Special Projects Manager Sydney Rachael Levin-Epstein posted a video on the campaign trail in Revere where a supporter smoking marijuana shouted “we’re with you” at the senator. He responded by saying “I support marijuana, by the way.”

Source: https://www.leafly.com/news/politics/massachusetts-senate-primary-begs-the-question-which-candidate-loves-legalization-least

Heartland

Watermelon Dream Sauce

Republished by Plato

Published

on

Visit our community site for vetted suppliers at http://theCBD.place. It’s time that this subject was given more internet exposure. We are here to discuss topics related to medical marijuana and our experiences using CBD. Please do not assume that anyone here is a medical professional.

Source: https://www.reddit.com/r/CBD/comments/jgxl3l/watermelon_dream_sauce/

Continue Reading

Heartland

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of […]

The post Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals appeared first on CannabisFN.

Republished by Plato

Published

on



Ryan Allway

October 23rd, 2020

Psychedelics


Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle (“GelMA-MN”) delivery technology developed at the University of California, Los Angeles (“UCLA”) for use with psychedelic pharmaceuticals, including, but not limited to Psilocybin, Ketamine, Ibogaine, LSD, MDMA, DMT, and Cannabinoids.

“We are very pleased to have acquired the rights to this novel microneedle delivery technology as it strengthens the foundation of our strategy to develop and commercialize a unique pipeline of psychedelic pharmaceuticals for FDA approval and I believe puts us in the conversation with companies such as Compass Pathways and Mind Medicine, who are leading the way in psychedelic medicines,” said Fabio Chianelli, Chief Executive Officer of Pharmather. “The GelMA-MN delivery technology is complementary to our approach in finding new uses and combinations of psychedelics to improve therapeutic and safety outcomes while potentially offering a differentiated product profile, improving patient compliance and enabling out-patient treatment options. We are focused on realizing the potential of the GelMA-MN delivery technology and it will open up new market opportunities in multi-billion dollar categories such as mental health, nervous system disorders, pain, skin cancer, wounds, mucosal diseases and surgical applications.”

“We are pleased to partner with Pharmather and to realize the commercial potential of the GelMA-MN delivery technology as a unique delivery system for treating unmet medical needs,” said Dr. Ali Khademhosseini, Co-Founder of BioRAE, Inc. and Co-Inventor of GelMA-MN delivery technology.

About GelMA-MN Delivery Technology

The GelMA-MN (Figure 1) delivery technology was invented and developed by the members of the Khademhosseini Lab at UCLA. Studies have shown that GelMA can be used for the fabrication of MN arrays and the delivery of both water-soluble and insoluble drugs with desirable release profiles. GelMA is derived from the natural polymer gelatin with crosslinkable methacrylate group making it an ideal candidate for MN fabrication and various other biomedical applications. The GelMA-MNs are biocompatible and biodegradable, can efficiently penetrate the stratum corneum layer (outer layer of the skin), enable flexible drug load capacity and combinations, and control-release delivery. MNs are considered as a promising way to achieve systemic effects by transdermal delivery of drugs. In addition to applications on the skin, MNs may be applied in other organs and tissues like the eyes and mucosal surfaces. MNs are minimally invasive, painless, and may overcome the potential drawbacks of oral administration, subcutaneous injections and other transdermal delivery systems.

Under the terms of the Agreement, the Company gained exclusive worldwide rights to intellectual property to develop and commercialize the GelMA-MN delivery technology with psychedelics, cannabinoids, and various compounds for therapeutic uses. Consistent with industry standards, Pharmather will pay a one-time fee for entering into the Agreement and all other future payments will be based on clinical trial and revenue milestones reached by Pharmather in the future.

About Pharmather Inc.

Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets. Our goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and our clinical product pipeline with ketamine and psilocybin in the treatment of Parkinson’s Disease, depression, traumatic brain injury and stroke. Learn more at: pharmather.com and follow us on FacebookTwitter and LinkedIn.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Source: https://www.cannabisfn.com/pharmather-secures-exclusive-rights-to-novel-microneedle-delivery-technology-for-psychedelic-pharmaceuticals/

Continue Reading

Heartland

Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health

Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce that it has entered into a non-binding letter of intent dated October 16, 2020 (the “LOI“), which sets out basic terms and conditions for the acquisition by Mind Cure of Ephiphany360, a proprietary cloud-based digital therapeutics platform for treating mental health. The […]

The post Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health appeared first on CannabisFN.

Republished by Plato

Published

on



Ryan Allway

October 23rd, 2020

Psychedelics


Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce that it has entered into a non-binding letter of intent dated October 16, 2020 (the “LOI“), which sets out basic terms and conditions for the acquisition by Mind Cure of Ephiphany360, a proprietary cloud-based digital therapeutics platform for treating mental health.

The Epiphany360 platform has been clinically validated on more than 10,000 patients over the last 20 years. Four feasibility studies are currently underway, the protocols of which have been designated ‘non-significant risk.’ The data being collected will form part of Epiphany360’s submission to the FDA for clearance as a Class II medical device.

“We are accelerating our move into digital therapeutics with the Epiphany360 platform to bring evidence-based insights in the diagnoses and treatment of patients suffering from mental health related illness,” stated Philip Tapley, Mind Cure Chairman, President, and CEO. “Technology innovation has a key role to play in modern healthcare as we look to find new and more effective ways to treat mental health. Epiphany360 will enable Mind Cure to more effectively create and evaluate products, drugs and therapies.”

Dr. Antonio Ocana, the Founder of Epiphany360, said, “We created the Epiphany360 platform to address the devastation experienced by individuals, families and society in the wake of the tragedy associated with mental health and addiction. It’s like a dream come true to work side by side with Mr. Tapley and the Mind Cure team. Together we will optimize the technology that will finally co-ordinate care between doctors, therapists and patients, ultimately, making these solutions accessible to researchers, employers and insurers who will benefit from the improved outcomes and lower healthcare costs. We feel very lucky to have Mind Cure’s scientific advisory team alongside as we move towards regulatory approval.”

The mental health crisis, made worse by COVID-19, is impacting hundreds of millions of people, lowering productivity and increasing absenteeism and disability, the global burden of which is estimated at more than $1 trillion annually. Mind Cure believes that the application of digital therapeutics can unlock immense value, both enhancing patient access and engagement, as well as making mental health treatment safer and more effective.

About Epiphany360

Epiphany360 is a proprietary and cloud-based digital therapeutics platform. It monitors, collects and generates evidence-based insights to optimize treatment and improve patient outcomes in mental health-related conditions. It is powered by proprietary software that compares treatments and outcomes to continuously improve the validity and accuracy of unique patient care options and is backed by 25 years of clinical experience and scientific data.

Four feasibility studies are currently underway, the protocols of which have been designated ‘non-significant risk.’ The data being collected will form part of Epiphany360’s submission to the FDA for clearance as a Class II medical device.

About Mind Cure Health Inc.

Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure.

Pursuant to the LOI, the parties intend to negotiate the terms of a definitive agreement (the “Definitive Agreement“), which will provide for, among other things the acquisition by Mind Cure of substantially all the assets of Epiphany360 in exchange for $2,000,000 of common shares in the capital of Mind Cure based on the ten day volume weighted average price of Mind Cure’s common shares on the Canadian Securities Exchange immediately prior to the closing date (the “Purchase Shares“). The Purchase Shares will be subject to an escrow agreement to be released as follows: 15% released immediately at closing, and the balance to be released in six equal installments every six months for 36 months. There can be no assurance that the Definitive Agreement will be entered into or that the acquisition will be completed on the terms proposed in the LOI or at all.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Source: https://www.cannabisfn.com/mind-cure-announces-loi-for-acquisition-of-epiphany360-digital-therapeutics-platform-for-treating-mental-health/

Continue Reading
Heartland3 days ago

Web site credit card processing

Manufacturing2 days ago

New and Noteworthy Categories on Thomasnet.com for October 2020

Heartland3 days ago

CBG Study Shows Antimicrobial Properties of Cannabis

Heartland2 days ago

Medical Marijuana: 7 Incredible Health Benefits for Women

Heartland2 days ago

German Cannabis Flower Market is Ready to Explode

CBD4 days ago

CBD and Geriatric Medicine: Should Seniors Take CBD?

Heartland4 days ago

CBG tinctures

Heartland4 days ago

Best CBD topical for Trigger Points?

Heartland4 days ago

Where do I start for depression?

Heartland3 days ago

Find your perfect sleep system

Heartland2 days ago

Cybin Raises C$45 Million: The Largest Go Public Capital Raise in the Canadian Psychedelic Sector

Heartland4 days ago

CBD for anxiety/sleep

CBD4 days ago

CBD News: Hemp Industry Daily launches annual industry survey for business data

Heartland4 days ago

CBD & Cannabis for Endometriosis

Heartland3 days ago

Thanks to these CBD “cigarettes” I am a full week tobacco/nicotine free 🎉

Heartland1 day ago

Dosage for CBG/CBD tincture from LN?

Heartland4 days ago

Caught my Jack-o’-lantern enjoying a CBD joint

Heartland5 days ago

Took too much CBD oil three days ago and still feeling the effects

Heartland5 days ago

Natural d hist and CBD oil/ insomnia

Uncategorized5 days ago

7 Ways to Celebrate Halloween Responsibly With Cannabis

Heartland4 days ago

The Daily Hit: October, 19th 2020

Manufacturing3 days ago

Look ! so lovely and warm smile@v@

Heartland2 days ago

Will I get high from a gummy with 4.5 mg cbd and .5 mg thc? I have no tolerance.

Heartland1 day ago

Indus Holdings, Inc. Welcomes Bruce Gates to Board of Directors; Announces Results of Annual Shareholder Meeting

Heartland5 days ago

High Times Greats: Divine

Heartland5 days ago

Havn Life Applies for License to Produce and Sell Psilocybin

Heartland5 days ago

CBD Vape Carts

Heartland5 days ago

What CBD/hemp flower reviewers do you trust?

Heartland4 days ago

Very high volume CBD users – any withdrawal symptoms?

Heartland4 days ago

Brand Spotlight: Cannabiotix

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America